$-0.10
(Market cap
$577 Mln
Recently Viewed
Clear AllMarket cap
$577 Mln
Revenue (TTM)
$312 Mln
P/E Ratio
3.6
P/B Ratio
1.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
3.5
Debt to Equity
0.4
Book Value
$4.3
EPS
$1.7
Face value
--
Shares outstanding
79,050,395
CFO
$-214.34 Mln
EBITDA
$-266.00 Mln
Net Profit
$-265.84 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
CorMedix (CRMD)
| -38.7 | 10.5 | 1.7 | -3.6 | 10.6 | -1.4 | -9.9 |
|
BSE Sensex
| -7.9 | 4.6 | -6.5 | 1.6 | 8.9 | 9.8 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
CorMedix (CRMD)
| 43.6 | 114.1 | -10.9 | -7.3 | -38.8 | 2.1 | 12.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
CorMedix (CRMD)
|
7.1 | 577.1 | 311.7 | 163.1 | 48.2 | 66.6 | 3.6 | 1.4 |
| 13.1 | 4,185.3 | 3,018.8 | 72.1 | 12.6 | -80 | 59.6 | 105.4 | |
| 40.9 | 5,222.3 | 1,003.8 | 22.4 | 6.8 | 7.5 | 226.9 | 14.1 | |
| 184.2 | 9,421.4 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 106.7 | |
| 77.5 | 15,107.7 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 44.0 | 4,646.4 | 761.4 | 99.7 | 7.3 | 15 | 53.3 | 7.1 | |
| 13.1 | 11,112.5 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18 | 2.7 | |
| 23.1 | 11,915.2 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.6 | 6,866.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.1 | 0.9 | |
| 223.2 | 4,633.1 | 268.1 | 124.5 | 60.0 | 13.5 | 37.9 | 4.2 |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock... solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey. Address: 389 Interpace Pkwy, Parsippany, NJ, United States, 07054 Read more
CEO & Director
Mr. Joseph Todisco MBA
CEO & Director
Mr. Joseph Todisco MBA
Headquarters
Parsippany, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of CorMedix Inc (CRMD) is $7.13 (NASDAQ) as of 16-Apr-2026 16:21 EDT. CorMedix Inc (CRMD) has given a return of 10.6% in the last 3 years.
The P/E ratio of CorMedix Inc (CRMD) is 3.58 times as on 15-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
6.70
|
2.69
|
|
2024
|
-27.79
|
5.89
|
|
2023
|
-4.66
|
3.08
|
|
2022
|
-5.95
|
3.21
|
|
2021
|
-6.15
|
2.76
|
The 52-week high and low of CorMedix Inc (CRMD) are Rs 17.43 and Rs 6.13 as of 17-Apr-2026.
CorMedix Inc (CRMD) has a market capitalisation of $ 577 Mln as on 15-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in CorMedix Inc (CRMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.